Literature DB >> 30151079

Chemical modulation of transcription factors.

Bianca Wiedemann1, Jörn Weisner1, Daniel Rauh1.   

Abstract

Transcription factors (TFs) constitute a diverse class of sequence-specific DNA-binding proteins, which are key to the modulation of gene expression. TFs have been associated with human diseases, including cancer, Alzheimer's and other neurodegenerative diseases, which makes this class of proteins attractive targets for chemical biology and medicinal chemistry research. Since TFs lack a common binding site or structural similarity, the development of small molecules to efficiently modulate TF biology in cells and in vivo is a challenging task. This review highlights various strategies that are currently being explored for the identification and development of modulators of Myc, p53, Stat, Nrf2, CREB, ER, AR, HIF, NF-κB, and BET proteins.

Entities:  

Year:  2018        PMID: 30151079      PMCID: PMC6097187          DOI: 10.1039/c8md00273h

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  211 in total

1.  Mechanism of lower genotoxicity of toremifene compared with tamoxifen.

Authors:  S Shibutani; A Ravindernath; I Terashima; N Suzuki; Y R Laxmi; Y Kanno; M Suzuki; T I Apak; J J Sheng; M W Duffel
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

Review 2.  Function and regulation of CREB family transcription factors in the nervous system.

Authors:  Bonnie E Lonze; David D Ginty
Journal:  Neuron       Date:  2002-08-15       Impact factor: 17.173

Review 3.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

4.  The transcriptional coactivators p300 and CBP are histone acetyltransferases.

Authors:  V V Ogryzko; R L Schiltz; V Russanova; B H Howard; Y Nakatani
Journal:  Cell       Date:  1996-11-29       Impact factor: 41.582

5.  Commentary on "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer." Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J, Division of Urologic Oncology, Department of Urology, University of Michigan, MI. N Engl J Med 2014; 371(11):1028-38.

Authors:  Ganesh S Palapattu
Journal:  Urol Oncol       Date:  2016-03-07       Impact factor: 3.498

Review 6.  Androgens and osteoporosis.

Authors:  Peter R Ebeling
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-06       Impact factor: 3.243

7.  Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.

Authors:  Michelle A Blaskovich; Jiazhi Sun; Alan Cantor; James Turkson; Richard Jove; Saïd M Sebti
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

8.  Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.

Authors:  Karim Fizazi; Christophe Massard; Petri Bono; Robert Jones; Vesa Kataja; Nicholas James; Jorge A Garcia; Andrew Protheroe; Teuvo L Tammela; Tony Elliott; Leena Mattila; John Aspegren; Annamari Vuorela; Peter Langmuir; Mika Mustonen
Journal:  Lancet Oncol       Date:  2014-06-25       Impact factor: 41.316

9.  Allosteric inhibition of hypoxia inducible factor-2 with small molecules.

Authors:  Thomas H Scheuermann; Qiming Li; He-Wen Ma; Jason Key; Lei Zhang; Rui Chen; Joseph A Garcia; Jacinth Naidoo; Jamie Longgood; Doug E Frantz; Uttam K Tambar; Kevin H Gardner; Richard K Bruick
Journal:  Nat Chem Biol       Date:  2013-02-24       Impact factor: 15.040

10.  Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Chandtip Chandhasin; Erica Osbourne; Jun Luo; Marianne D Sadar; Frank Perabo
Journal:  Oncologist       Date:  2016-09-14
View more
  3 in total

Review 1.  Current strategies and progress for targeting the "undruggable" transcription factors.

Authors:  Jing-Jing Zhuang; Qian Liu; Da-Lei Wu; Lu Tie
Journal:  Acta Pharmacol Sin       Date:  2022-02-07       Impact factor: 7.169

2.  MicroRNA-related transcription factor regulatory networks in human colorectal cancer.

Authors:  Shuhong Hao; Sibo Huo; Zhenwu Du; Qiwei Yang; Ming Ren; Shui Liu; Tongjun Liu; Guizhen Zhang
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

Review 3.  Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity.

Authors:  Dominique R Perez; Larry A Sklar; Alexandre Chigaev; Ksenia Matlawska-Wasowska
Journal:  Semin Cancer Biol       Date:  2020-02-07       Impact factor: 15.707

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.